Scholarlink

Purpose of Review <p>This review underscores the importance of appropriate clinical application and long-term pharmacovigilance for resmetiron.</p> Recent Findings <p>Resmetirom is a highly selective thyroid hormone receptor-β (THR-β) agonist with pronounced hepatic specificity, which modulate lipid metabolism, thereby reducing hepatic steatosis, inflammation, and fibrosis, while minimizing off-target effects on other tissues. In 2024, the U.S. Food and Drug Administration (FDA) approved resmetirom as the first pharmacologic treatment for non-cirrhotic metabolic-associated steatohepatitis with moderate to advanced liver fibrosis.</p> Summary <p>Resmetirom is a highly selective THR-β agonist that has demonstrated promising efficacy and acceptable tolerability in phase III trials and received FDA approval as the first drug for MASH treatment. Long-term safety and post-marketing studies with large sample sizes are warranted to monitor additional benefits as well as potential adverse effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Resmetirom in the Management of MASLD: What Clinicians Need to Know

  • 期刊论文

  • 发表日期：

    2025年12月2日

查看全文
  • Weiwei Xu,
  • Manuel Romero-Gómez,
  • Vicente Artola Arita

摘要

Purpose of Review

This review underscores the importance of appropriate clinical application and long-term pharmacovigilance for resmetiron.

Recent Findings

Resmetirom is a highly selective thyroid hormone receptor-β (THR-β) agonist with pronounced hepatic specificity, which modulate lipid metabolism, thereby reducing hepatic steatosis, inflammation, and fibrosis, while minimizing off-target effects on other tissues. In 2024, the U.S. Food and Drug Administration (FDA) approved resmetirom as the first pharmacologic treatment for non-cirrhotic metabolic-associated steatohepatitis with moderate to advanced liver fibrosis.

Summary

Resmetirom is a highly selective THR-β agonist that has demonstrated promising efficacy and acceptable tolerability in phase III trials and received FDA approval as the first drug for MASH treatment. Long-term safety and post-marketing studies with large sample sizes are warranted to monitor additional benefits as well as potential adverse effects.